Quoin Pharmaceuticals QNRX
- Market cap
- $8.1M
- PE
- n/m
- a loss over the last year
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- n/m
- not a meaningful number
- EV/EBIT
- n/m
- not a meaningful number
- Revenue, 12 months
- n/m
- not a meaningful number
- Net margin
- n/m
- not a meaningful number
- Free cash flow yield
- n/m
- not a meaningful number
Quoin Pharmaceuticals' trailing earnings are negative, so it has no PE.
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| R&D | $758.8K+2% | $832.4K+36% | $885.3K−19% | $587.5K−6% | $1.1M+42% | $1.1M+26% | $2.4M+168% | $2.1M+249% | $2.3M+111% | $3.1M+195% | $3.4M+45% | $3.6M+77% |
| SG&A | $1.4M−14% | $1.4M−6% | $1.6M−7% | $1.5M−5% | $1.4M+6% | $1.4M−2% | $1.6M+1% | $1.7M+13% | $1.7M+20% | $1.4M+5% | $1.7M+7% | $1.8M+6% |
| Net income | −$1.9M−36% | −$2M+2% | −$2.3M−11% | −$2M−6% | −$2.3M+22% | −$2.3M+13% | −$3.8M+64% | −$3.7M+87% | −$3.9M+68% | −$4.3M+88% | −$5M+31% | −$5.4M+45% |
| −$1.95−83% | −$2.08 | −$38.73+847% | −$13.68+542% | −$16.29+735% | −$13.00+525% | −$6.50−83% | −$6.28−54% | −$6.71−59% | −$1.74−87% | −$1.77−73% | −$1.90−70% | |
| 987.2K+260% | 987.2K | 60.1K−91% | 144.3K−85% | 144.3K−85% | 177.7K−82% | 586.3K+876% | 588.2K+308% | 588.2K+308% | 2.5M+1303% | 2.8M+383% | 2.8M+382% |
EPS, diluted: 3 periods, Q4 FY23 to Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: 3 periods, Q4 FY23 to Q4 FY25: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Drug Manufacturers - General nearest Quoin Pharmaceuticals' size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| QNRXQuoin Pharmaceuticals | $8.1M | n/m | n/a | n/m | n/m | n/m | |
| ATNMActinium Pharmaceuticals | $47.8M | 4.2× | 3.1× | n/m | n/m | n/m | |
| SPROSpero Therapeutics | $64.6M | 10.1× | 9.5× | 1.4× | −3% | 15.7% | |
| LFVNLifevantage | $73.4M | 14.7× | 19.6× | 0.4× | −20% | 2.8% | |
| Peer median | $64.6M | 10.1× | 9.5× | 0.9× | −12% | 9.2% |
More on Quoin Pharmaceuticals
Each number over time
Its groups
About
- Industry
- Drug Manufacturers - General
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .